Circulating IL-18 Prognosis for Early NSCLC Recurrence Risk

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current prognostic models for early stage non-small cell lung cancer (NSCLC), particularly adenocarcinoma, lack sensitivity and specificity in predicting recurrence, leading to overtreatment and inadequate monitoring.

Innovation Solution

Utilizing elevated plasma Interleukin-18 (IL-18) levels to predict recurrence in NSCLC, guiding adjuvant therapy and monitoring decisions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current prognostic models based on classification and demographic predictors are used, then treatment decisions can be made, but the sensitivity and specificity for predicting recurrence are insufficient

Engineering Contradiction:

Improveprognostic prediction accuracyVSAvoidrecurrence prediction reliability

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent changes the parameter being measured from demographic and histologic classification data to a molecular biomarker (IL-18) concentration in plasma. This parameter change enables more sensitive and specific detection of recurrence risk, as IL-18 levels provide a direct molecular indicator of tumor presence and activity that overcomes the limitations of indirect demographic predictors.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If adjuvant therapy is administered to all patients with solid and/or micropapillary components, then some patients may benefit, but overtreatment occurs in patients who would not recur

Engineering Contradiction:

Improvetreatment necessity accuracyVSAvoidovertreatment harm

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses IL-18 plasma levels as a molecular copy or surrogate marker that accurately reflects the true recurrence risk state of the tumor. This molecular copy provides a more faithful representation of disease biology than histologic classification, enabling precise identification of which patients truly need adjuvant therapy versus those who would be harmed by overtreatment.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent replaces the mechanical/pathologic system of histologic classification and demographic assessment with a molecular detection system measuring IL-18 concentrations. This substitution enables more accurate risk stratification by directly detecting molecular indicators of recurrence risk rather than relying on indirect morphological proxies.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Ease of operation

If current prognostic models are used, then treatment planning can proceed, but recurrence may be missed in patients who need intensive monitoring

Engineering Contradiction:

Improvemonitoring guidanceVSAvoidrecurrence detection sensitivity

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent replaces indirect monitoring based on demographic risk factors with direct molecular monitoring of IL-18 levels. This substitution dramatically improves detection sensitivity by measuring actual molecular evidence of recurrence rather than inferring risk from population-based statistics, enabling timely intervention when recurrence occurs.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS12553897B2Use of circulating interleukin-18 for prognosticating and treating recurrence in early stage non-small cell lung cancer

Publication Date: 2026.02.17 NEW YORK UNIV

AI summary

Provided are methods for aiding in diagnosis and treatment of non-small cell lung cancer (NSCLC) adenocarcinoma. The methods involve determining elevated circulating Interleukin-18 (IL-18) values to aid in the diagnosis and treatment of NSCLC. Medical interventions based on determining circulating IL-18 levels are provided and include additional scanning, surgical resection of tumors, and administration of adjuvant therapy, such as chemotherapy or immune therapy.